Company research / WVE

Wave Life Sciences, Inc. (WVE)

CIK 0001631574 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Wave Life Sciences, Inc. reported revenue of $42.73M. Revenue fell 60.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $65.37M.

Key ratios (year ended 2025-12-31)

-504.1%
Operating margin
-478.3%
Net margin
-39.4%
Return on year-end equity
-60.5%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form DEF 14A (proxy statement) · 2026-10-14

Headquarters locality: Boston · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$65.37M$42.73M$108.30M$113.31M$3.65M$40.96M$20.08M$15.98M$14.41M$3.89M$1.09M
R&D Expense$197.42M$182.78M$159.68M$130.01M$115.86M$121.88M$130.94M$175.43M$134.43M$79.31M$40.82M
Operating Income-$217.92M-$215.38M-$110.40M-$68.00M-$162.72M-$127.02M-$153.38M-$208.32M-$159.52M-$102.39M-$55.72M
Depreciation & Amortizationn/an/an/an/an/an/an/an/an/a$2.15M$784.0K
EBITDAn/an/an/an/an/an/an/an/an/a-$100.24M-$54.94M
Net Income-$202.47M-$204.38M-$97.01M-$57.51M-$161.82M-$122.25M-$149.91M-$193.64M-$146.65M-$101.98M-$55.66M
EPS (Diluted)n/a-$1.21-$0.70-$0.54-$2.05-$2.36n/an/an/an/an/a
Total Assets$558.32M$638.50M$352.21M$274.95M$146.39M$207.01M$279.24M$284.25M$295.94M$181.84M$164.81M
Total Liabilities$104.80M$112.27M$134.82M$227.44M$183.60M$166.63M$188.59M$212.64M$214.72M$34.36M$22.07M
Shareholders' Equity$453.52M$518.36M$209.51M$39.63M-$45.09M$32.50M$82.78M$63.73M$73.35M$139.61M$134.60M
Cash & Equivalents$368.01M$602.07M$302.08M$200.35M$88.50M$150.56M$184.50M$147.16M$174.82M$142.50M$150.29M
Operating Cash Flow-$191.58M-$187.49M-$151.03M-$19.43M-$127.78M-$88.99M-$115.98M-$188.23M-$22.86M-$83.67M-$31.93M
Capital Expenditures$1.57M$718.0K$938.0K$1.11M$1.36M$560.0K$1.34M$3.92M$9.94M$18.89M$5.57M
Free Cash Flow-$193.15M-$188.21M-$151.96M-$20.55M-$129.14M-$89.55M-$117.32M-$192.15M-$32.80M-$102.56M-$37.49M
Shares Outstanding193.28M187.66M153.04M119.16M86.92M59.84M48.78M34.34M29.47M27.83M23.50M
Weighted Average Diluted Sharesn/a168.65M138.28M106.10M78.86M51.83Mn/an/an/an/an/a
EPS (Basic)n/a-$1.21-$0.70-$0.54-$2.05-$2.36n/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView